Previous 10 | Next 10 |
HOLON, Israel , Aug. 28, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent covering the comp...
The biotech industry has been on a tear as the search for coronavirus treatments heat up. Here are four biotech stocks that analysts love: Compugen (CGEN), Cerus (CERS), Mersana Therapeutics (MRSN) and Protagonist Therapeutics (PTGX). Wall Street analysts keep a close eye on price movement,...
Compugen Ltd (CGEN) Q2 2020 Earnings Conference Call July 30, 2020 08:30 AM ET Company Participants Elana Holzman - Investor Relations Anat Dayag - CEO Henry Adewoye - Chief Medical Officer Ari Krashin - CFO and COO Eran Ophir - VP Research and Drug Discovery Conference Ca...
Image source: The Motley Fool. Compugen Ltd. (NASDAQ: CGEN) Q2 2020 Earnings Call Jul 30, 2020 , 8:30 a.m. ET Operator Continue reading
Compugen (NASDAQ: CGEN ) : Q2 GAAP EPS of -$0.08 beats by $0.02 . More news on: Compugen Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
HOLON, Israel , July 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2020 . "We have reached an exciti...
COM701 Exhibits Compelling Anti-Tumor Activity in Diverse, Challenging Patient Population After languishing for the better part of five years, Compugen ( CGEN ) shares are up 140% YTD and more than 300% over the past 52 weeks. This recent price action is directly attributable to the firs...
Quick Take iTeos Therapeutics ( ITOS ) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a range of treatments for various cancers, including solid tumors. ITOS is pursuing treatments for...
HOLON, Israel , July 16, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2020 financial results on Thursday, July...
Don’t Believe In Penny Stocks? This Might Make You Think Twice What comes to mind when you think about penny stocks ? Low price stock, B.S. companies, or maybe even long-shot lottery tickets? There’s no right or wrong answer to this question but there is an answer to the next qu...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...